Item 8. CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The consolidated financial statements, with the report of the independent
auditors, listed in Item 14, are included in this Annual Report on Form 10-K.
Item 1.  Business
Item 2.  Properties
Item 3.  Legal Proceedings
Item 4.  Submission of Matters to a Vote of Security Holders
PART II.
Item 5. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
EXECUTIVE OFFICERS AND DIRECTORS
Our executive officers and directors are as follows     NAME          AGE  POSITION
Thomas D. Weldon.   44  Chairman
William A. Hawkins.   45  Chief Executive Officer,
President and Director
David N. Gill.   45  Chief Operating Officer and
Chief Financial Officer
Raoul Bonan, M.D.   52  Vice President, Clinical
Affairs and Medical Director
Michel E. Lussier.   43  Vice President, European Operations
Joan M. Macdonald, Ph.D. 42  Vice President, Regulatory Affairs
Cheryl R. Johnson.   37  Vice President, Investor Relations and
Business Development and Secretary
Adam G. Lowe..   37  Vice President, Quality
Assurance
Donald J. Webber..   37  Vice President, Manufacturing
Donald C. Harrison, M.D 65  Director2
J. Stephen Holmes.   56  Director1
Stephen I. Shapiro.   55  Director1
Charles E. Larsen.   48  Director
Pieter J. Schiller.   61  Director2
Norman R. Weldon, Ph.D  65  Director
William E. Whitmer.   66  Director2  1   Member of Stock Option and Compensation Committee.
2   Member of Audit Committee.
Thomas D. Weldon. Mr. Weldon co-founded the Company and has served as a
Director since our capitalization in May 1992, becoming Chairman in June 1998.
Mr. Weldon also served as Chief Executive Officer from May 1992 until April
1999, upon the promotion of Mr. Hawkins. On April 1, 1999 Mr. Weldon and Mr.
Larsen co-founded The Innovation Factory, a life sciences company incubator. Mr.
Weldon serves as the Chairman and Chief Executive Officer of The Innovation
Factory. Mr. Weldon co-founded and was President, Chief Executive Officer and a
Director of Novoste Puerto Rico Inc., a manufacturer of disposable
cardiovascular medical devices, from 1987 to May 1992, prior to its sale.
Previous responsibilities included management positions at Arthur Young &
Company and Key Pharmaceuticals. Mr. Weldon received a B.S. in Industrial
Engineering from Purdue University and an M.B.A. in Operations and Systems
Management from Indiana University.
William A. Hawkins. Mr. Hawkins was elected Director in May 1998, joined
the Company as President in June 1998 and became Chief Executive Officer in
April 1999. From April 1997 to May 1998, Mr. Hawkins was a Corporate Vice
President of American Home Products Corporation and President of its Sherwood
Davis & Geck division. He is a past board member of the Health Industry
Manufacturers Association HIMA. Since January 1995, he has been a director of
PharmaNetics, Inc., a Nasdaq-listed company. From October 1995 until April 1997,
Mr. Hawkins was President of Ethicon Endo-Surgery, Inc., a medical device
subsidiary of Johnson & Johnson. From January 1995 to October 1995, Mr. Hawkins
served as Vice President in charge of United States operations of Guidant
Corporation and President of Devices for Vascular Intervention, a medical device
company and a subsidiary of Guidant. Prior to joining Guidant, Mr. Hawkins held
several positions with IVAC Corporation, a medical device company, most recently
serving as President and Chief Executive Officer from 1991 until 1995. Mr.
Hawkins holds a B.S. in Engineering and Biomedical Engineering from Duke
University and an M.B.A. from the University of Virginia.
David N. Gill. Mr. Gill has served as the Company Chief Financial
Officer since July 1996 and as Chief Operating Officer since February 28, 1997.
From August 1995 to June 1996, Mr. Gill served as Chief Financial Officer of
SPEA Software AG prior to its sale. From 1992 to 1995, Mr. Gill served as
President and Director of Dornier Medical Systems, Inc., a medical device
company, and from                    29 1990 to 1992 as its Vice President of Finance. Mr. Gill received an M.B.A. from
Emory University and a B.S. degree in Accounting from Wake Forest University,
and is a Certified Public Accountant.
Raoul Bonan, M.D. Dr. Bonan, an interventional cardiologist, joined
Novoste as Medical Director and V.P., Clinical Affairs in June 1998 upon taking
a leave of absence from the Montreal Heart Institute where he has been a staff
member from 1978 until May 1998, and was Chief of the Cardiac Catheterization
Laboratory from 1986 to 1994. In September 1999 Dr. Bonan completed his leave of
absence and returned to clinical practice at the Montreal Heart Institute. He
has agreed to continue to serve as our Medical Director and Vice President of
Clinical Affairs on a part-time basis through August 31, 2000. Dr. Bonan was a
clinical investigator in the Beta-Cath System Trial and the BERT Trial prior to
joining Novoste. Dr. Bonan is a Fellow of the American College of Cardiology,
the European Society of Cardiology, and the American Heart Association.
Additionally, he serves on the editorial and review boards of several medical
journals, including Circulation and the Journal of the American College of
Cardiology. Dr. Bonan received a B.A. degree in Mathematics and his Medical
Degree in Paris, France. Dr. Bonan subsequently completed internships and
postgraduate training in Paris and Montreal, Canada.
Michel E. Lussier. Mr. Lussier joined Novoste as Vice President and
General Manager, European Operations in October 1998. Mr. Lussier served as Vice
President and General Manager of European Operations for InControl Inc., a
medical device company, from September 1994 until September 1998, when the
company was acquired by Guidant Corporation. From 1980 to 1994 Mr. Lussier was
employed by Medtronic, Inc., a medical device company, most recently serving as
its European Business Director, Cardiac Pacing. Mr. Lussier is currently Vice
President of the International Association of Prosthesis Manufacturers IAPM
and Chairman of its Strategy Committee. Mr. Lussier holds a B.S. in Electrical
Engineering and an M.S. in Biomedical Engineering, both from the University of
Montreal, and he earned an M.B.A. from the European Institute of Business
Administration-INSEAD.
Joan M. Macdonald, Ph.D. Dr. Macdonald joined the Company in January 1994,
as our Director of Regulatory Affairs, served as our Vice President, Regulatory
and Clinical Affairs from January 1996 to May 1998 and has been our Vice
President, Regulatory Affairs since June 1998. From September 1990 through
September 1993, Dr. Macdonald worked for CIBA Vision Corporation, a manufacturer
of ophthalmic products, having served most recently as Director, Worldwide
Regulatory Strategy. Dr. Macdonald received a Ph.D. degree in Physiology from
the Medical College of Wisconsin and M.S. and B.S. degrees in Zoology from the
University of Wisconsin.
Cheryl R. Johnson. Ms. Johnson joined the Company in July 1992 as Director
of Marketing and Business Development and Secretary, served as Director of
Administration and Business Development of the Company from January 1995 until
July 1996 and has served as Vice President, Investor Relations and Business
Development from July 1996. From August 1989 to June 1992, Ms. Johnson worked in
planning and business development capacities at BOC Health Care, most recently
as its business development manager. Ms. Johnson received an M.B.A. from the
Kellogg School at Northwestern University and a B.S. degree in Chemical
Engineering from the Georgia Institute of Technology.
Adam G. Lowe. Mr. Lowe joined the Company in June 1999 as our Vice
President, Quality Assurance. From July 1993 to June 1999 Mr. Lowe worked for
various divisions of C.R. Bard, Inc., a diversified medical device manufacturer,
having served most recently as the Vice President, Quality at Bard Access
Systems. Mr. Lowe received a B.S. in Materials Science and Engineering from
North Carolina State University and became an ASQ Certified Quality Engineer in
1992.
Donald J. Webber. Mr. Webber joined the Company in March 1998 as Director
of Manufacturing and has served as our Vice President, Manufacturing since
January 2000. From July 1996 through March 1998, Mr. Webber worked for Abiomed,
Inc., a manufacturer of cardiac products, as Director of Operations. From
January 1995 to July 1996, Mr. Webber was employed by Cabot Medical Corporation,
a medical device manufacturer, as Plant Manager and from 1988 to 1995 he was
employed by Cordis Corporation, a manufacturer of cardiovascular products. Mr.
Webber received an MBA from Nova Southeastern University and a B.S. degree in
Industrial Engineering from the State University of New York, Binghamton.
Donald C. Harrison, M.D. Dr. Harrison was elected a Director of the
Company in December 1998. He has been Professor of Medicine and Cardiology,
University of Cincinnati, and Senior Vice President and Provost for Health
Affairs, University of Cincinnati Medical Center, since 1986. Dr. Harrison has
been a director of EP Technologies, Inc., InControl Inc. and SciMed Life
Systems, Inc., is currently a member of the Medical Advisory Board of The
Proctor & Gamble Company and also serves as a director of four private,
healthcare-related companies. He is a past President of the American Heart
Association and was Chief of Cardiology at Stanford University School of
Medicine. Dr. Harrison holds an M.D. from University of Alabama School of
Medicine and a B.S. in Chemistry from Birmingham Southern College.                    30    J. Stephen Holmes. Mr. Holmes has served as a Director of the Company
since October 1992. He became President of Weck Closure Systems, a medical
device company, in February 1998. For two years prior thereto, Mr. Holmes was
Executive Manager of Saber Endoscopy, LLC, a medical device company he formed in
February 1996. From 1992 through 1995, Mr. Holmes was a private investor, having
founded several start-ups from 1979 through 1991, including Adler Instrument
Company, Inc., SOLOS Ophthalmology, Inc. and SOLOS Endoscopy, Inc., which he
founded in 1982, 1988 and 1990, respectively, and in which he sold his interests
in 1988, 1991 and 1991, respectively. Mr. Holmes received a B.S. in Marketing
from the University of Evansville.
Charles E. Larsen. Mr. Larsen co-founded the Company and has served as a
Director since our capitalization in May 1992. From February 28, 1997 until May
3, 1999 Mr. Larsen was Senior Vice President and Chief Technical Officer of the
Company, having served from May 1992 through February 1997 as our Senior Vice
President and Chief Operating Officer. Effective May 3, 1999, Mr. Larsen
resigned as an employee of Novoste and signed a one-year agreement to provide
technical consulting services. On April 1, 1999 Mr. Larsen co-founded The
Innovation Factory, a life sciences company incubator, with Mr. Weldon. Mr.
Larsen serves as the President of The Innovation Factory. Mr. Larsen co-founded
and was Vice President and Director of Novoste Puerto Rico, Inc. from 1987 to
May 1992. From 1983 through 1987, Mr. Larsen was a manager of manufacturing
engineering at Cordis Corporation. Mr. Larsen received a B.S. in Mechanical
Engineering from New Jersey Institute of Technology.
Stephen I. Shapiro. Mr. Shapiro has served as a Director of the Company
since October 1996. Mr. Shapiro previously served as a Director of the Company
from August 1995 until his resignation in March 1996. Since 1982, he has been a
Managing Principal of The Wilkerson Group, now integrated into IBM healthcare
consulting group with clients in the health care industry. Since 1999, he has
also been employed with two venture capital firms, Advanced Technology Ventures
and Galen Associates. From 1970 to 1982, Mr. Shapiro held a variety of technical
management and strategic planning positions with Union Carbide Clinical
Diagnostics and Becton Dickinson and Company. Mr. Shapiro received a B.S. degree
in Chemical Engineering from the Massachusetts Institute of Technology and an
M.S. degree in Chemical Engineering from the University of California at
Berkeley.
Pieter J. Schiller. Mr. Schiller has served as a Director of the Company
since March 1996. Since 1987, Mr. Schiller has been a general partner of
Advanced Technology Ventures ATV, a venture capital firm located in Waltham,
Massachusetts, where he specializes in health care investing. Mr. Schiller
served as a Director of CollaGenex Phamaceuticals, Inc. from September 1995
until June 1999. In addition, he currently serves as a director of eight
private, health-care related companies as a representative of ATV. Prior to ATV,
Mr. Schiller served Allied Signal and its predecessor companies from 1961
through 1986 in various capacities, including Treasurer and Vice-President,
Planning and Development. From 1983 to 1986, he served as Executive
Vice-President of Allied Health and Scientific Products Company, a
multi-national manufacturer of biomedical and analytical instruments and
supplies. Mr. Schiller received his M.B.A. from New York University and a B.A.
in Economics from Middlebury College.
Norman R. Weldon, Ph.D. Dr. Weldon co-founded the Company and was Chairman
of the Board from our capitalization in May 1992 until May 1998. Dr. Weldon is
Treasurer and Managing Director of Partisan Management Group, a venture capital
fund he co-founded in 1993. Dr. Weldon serves on the Advisory Board of the
Investment Company of America and as a director of two of its funds. From 1986
until May 1996, Dr. Weldon served as President and Chief Executive Officer and
as a Director of Corvita Corporation, a medical device company Dr. Weldon
co-founded in 1986. In July 1996 Pfizer Inc. consummated its acquisition of
Corvita. From 1979 to 1987, Dr. Weldon served as President and Chief Executive
Officer of Cordis Corporation. From 1964 to 1979, Dr. Weldon served CTS
Corporation in various capacities, including as its President and Chief
Executive Officer beginning in 1976. Dr. Weldon received, from Purdue
University, a Ph.D. in Economics, an M.S. in Industrial Management and a B.S. in
Biochemistry.
Dr. Norman R. Weldon is the father of Mr. Thomas D. Weldon.
William E. Whitmer. Mr. Whitmer has served as a Director of the Company
since October 1992. Mr. Whitmer is a Certified Public Accountant and management
consultant. From 1989 until his retirement in 1992, he was a partner of Ernst &
Young, having served as the Associate Managing Director of that firm southern
United States management consulting group. From 1968 through 1989, Mr. Whitmer
was a partner of Arthur Young & Company, having served as the Managing Partner
of its East and Southeast United States regions of the management consulting
practice from 1975 through 1989. Mr. Whitmer received a B.A. in Economics from
Denison University.
The Company Board of Directors is divided into three classes, each of
which will serve a term of three years, with one class being elected each year.
Each of the Company directors has been elected to serve until his successor
has been elected and duly qualified. The terms of the Class I directors: J.
Stephen Holmes, William E. Whitmer and Stephen I. Shapiro, will expire at the
annual meeting of shareholders in 2000; the terms of the Class II directors: Dr.
Donald C. Harrison, William A. Hawkins and Pieter J.                    31 Schiller, will expire at the annual meeting of shareholders in 2001; the terms
of the Class III directors: Thomas D. Weldon, Charles E. Larsen and Norman R.
Weldon, will expire at the annual meeting of shareholders in 2002.
The Board of Directors has a Stock Option and Compensation Committee,
comprised of J. Stephen Holmes and Stephen I. Shapiro. The Stock Option and
Compensation Committee establishes compensation policies and determines
compensation for our executive officers, as well as administering the Company
1992 Amended and Restated Stock Option Plan. The Board itself administers the
Non-Employee Director Stock Option Plan. The Board of Directors also has an
Audit Committee, comprised of Messrs. Donald C. Harrison, William E. Whitmer and
Pieter J. Schiller. The Audit Committee reviews our audit and financial
procedures and recommends any changes with respect thereto to the Board of
Directors.
Officers are elected annually and serve at the pleasure of the Board of
Directors.
We have obtained key-man life insurance policies on the lives of Mr.
Thomas D. Weldon and Mr. Larsen in the amount of $1,000,000 and $750,000,
respectively, under each of which we are the sole beneficiary.
COMPENSATION OF DIRECTORS
Non-employee directors are reimbursed their expenses and receive a fee of
$2,000 per Board meeting attended. Such directors who are members of a committee
of the Board of Directors receive a fee of $2,000 annually per committee in
which such director is a member, regardless of the number of committee meetings
attended by such director during the course of the year. On November 12, 1999
the Board granted each of its non-employee directors a five-year non-qualified
stock option to purchase 5,000 shares of our common stock at an exercise price
of $1375 per share. All of these options become exercisable at the earlier of
March 31, 2001 or the date of the 2001 Annual Meeting. Vesting of these options
ceases on such date as the option holder ceases to serve as a director.
